Several studies sponsored by Invitae underscore the importance of genetic testing for improving cancer outcomes, according to the company. These data will be presented at the 2022 ASCO annual meeting.
First-line treatment with the triplet combination of encorafenib, cetuximab, and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according to new data from the phase III BREAKWATER trial led by researchers from the University of Texas MD Anderson Cancer Center.
